All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

A bipartisan set of lawmakers is introducing a bill that seeks to reverse the Trump administration’s staffing cuts at a program that helps Americans afford heat and air conditioning. Reps. Josh ...

A disaster recovery program in California includes help for forward and reverse mortgage borrowers, drawing praise from reverse professionals.

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Howard U. program aims to reverse declining Black male enrollment at HBCUs Howard University is also focusing on middle school students and growing partnerships with nearby school districts to ...

In Our View Editorial: Reverse ruinous cuts to federal library program The Trump administration’s shuttering of the IMLS will be felt at the local and state levels. Saturday, April 12, 2025 1 ...